All News
FDA Approves Taltz for Psoriasis
Tuesday the FDA approved the IL-17 inhibitor, Taltz (ixekizumab) for adults with moderate to severe plaque psoriasis. (Citation source http://buff.ly/1py10wd)
Read ArticleStatin-Induced Autoimmune Myopathy
The CDC estimates nearly 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia use a cholesterol-lowering
Read ArticleHemochromatosis Reviewed
Powell et al have published in Lancet a review of hemochromatosis; its genetics, pathogenesis, clinical manifestations and management.
Read ArticleMMWR Update on Zika Virus: 116 US Cases Related to Travel
The Centers for Disease Control and Prevention (CDC) reported that in the last year (January 2015 to February 2016), they have identified and confirmed 116 cases of the Zika virus among US residents, with nearly all having traveled to endemic regions.
Read ArticleDifferences in Diuretic-Induced Gout
Diuretics are frequently implicated causes of hyperuricemia and gout. And there are gout variants wherein age, renal dysfunction and diuretic use may give rise to gouty attack in the hands of women with nodal osteoarthritis.
Read ArticleThe Week in Review 18 March 2016
See the highlights from the past week that appeared on RheumNow.com, and watch Dr. Jack Cush as he reviews each of them.
Read ArticleDoes Your Hospital Staff Include a Donald Trump?
When Donald Trump announced that he was running for president last summer, most people didn't know quite what to think. Was this serious or some sort of publicity stunt? Would he be in the race for more than just a few weeks of intense media spotlight?
Read ArticleBisphosphonate Use Falls Following FDA Warnings
In the current issue of JBMR, Kim and colleagues from Brigham and Women's Hospital in Boston assessed US claims data and studied the impact of three FDA drug safety warnings regarding the use of bisphosphonates.
Read ArticleAcetaminophen: No Effect in Osteoarthritis Pain or Function
A network analysis of multiple therapies used in osteoarthritis found that acetaminophen (paracetamol) does not meet the minimum standard of clinical effectiveness in reducing pain or improving physical function in patients with knee and hip osteoarthritis.
Read ArticleJanuary/February 2016 Top Social Media News
In February 2016, RheumNow published 82 tweets about impactful news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 80,800 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.
Read ArticleSclerostin Inhibition May Worsen Rheumatoid Arthritis
Sclerostin, an inhibitor of the Wnt/β-catenin pathway, negatively regulates osteoblast differentiation and has anti-anabolic effects on bone formation. Thus, inhibition of sclerostin is currently being studied as therapy for postmenopausal osteoporosis.
Read ArticleTNF Inhibitors Increase Perioperative Infection Risk
The use of tumour necrosis factor α inhibitors (TNFis) at the time of major surgery has been a challenge for surgeons, rheumatologists and those wishing to develop evidence-based guidelines for this clinical scenario.
Read ArticleIL-6 Inhibition Makes News
Several new interleukin-6 inhibitors made headlines this week. While none of the new IL-6 inhibitors are soon to be approved and available, these studies may redefine the role of other non-TNF biologics in the future.
Read ArticleNews Bytes
Most medical school faculty don't have time to observe third- and fourth-year medical students doing a complete medical exam? In When Medical Students Push Back, Westby Fisher, MD, FACC, offers his take on unnecessary testing and this particular issue.
Read ArticleMinimal Disease Activity Falls Short in Psoriatic Arthritis
A small cohort study has evaluated the utility of the minimal disease activity (MDA) criteria that has been advocated for use in psoriatic arthritis (PsA) studies and clinical trials.
Read ArticleNew CDC Guidelines on Prescribing Opiates for Pain
The use of opioids has become increasingly problematic in the last few years. First, the rising rates of use and abuse, followed by greater restrictions and regulations that have curtailed use, and, finally, a resultant increase in illicit drug use (heroin) and opioid overdoses.
Read ArticleLeflunomide and Weight Loss in Rheumatoid Arthritis
Weight change can have substantial effects on the outcomes of patients with arthritis. It has long been known that weight loss and low body mass index (BMI) are associated with poorer arthritis outcomes.
Read ArticleRisk Factors for Pulmonary Hypertension in Lupus
Fidler and colleagues from Toronto have recently shown that pulmonary disease is common in lupus, as they found 56% of their patients with abnormal pulmonary assessments.
Read ArticleACR Invites Comment on Perioperative Management Guidelines
The ACR is inviting members and rheumatologists to comment on their proposal to develop recommendations for the "Perioperative Management of Rheumatic Disease Medications in Total Joint Arthroplasty of the Hip and Knee".
Read Article